Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089922 | 1.00 | ALOX5 (0.46) | ALOX5EPHX2KCNT1KCNQ2HDAC1 | |
| SCHEMBL3111409 | 0.86 | ALOX5 (0.44) | ALOX5EPHX2KCNT1KCNQ2LMNA | |
| SCHEMBL3104094 | 0.86 | KCNQ2 (0.48) | ALOX5EPHX2KCNT1KCNQ2HDAC1 | |
| SCHEMBL30794565 | 0.86 | KCNQ2 (0.48) | ALOX5EPHX2KCNT1KCNQ2HDAC1 | |
| SCHEMBL27749690 | 0.85 | GAA (0.48) | ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL30795774 | 0.83 | ALOX5 (0.43) | ALOX5EPHX2KCNT1HDAC1HDAC6 | |
| SCHEMBL3106729 | 0.83 | ALOX5 (0.43) | ALOX5EPHX2KCNT1HDAC1HDAC6 | |
| SCHEMBL3104063 | 0.83 | ALOX5 (0.55) | ALOX5EPHX2KCNT1KCNQ2HDAC1 | |
| SCHEMBL30795194 | 0.83 | ALOX5 (0.55) | ALOX5EPHX2KCNT1KCNQ2HDAC1 | |
| SCHEMBL3106549 | 0.83 | ALOX5 (0.62) | ALOX5EPHX2KCNT1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |